Safety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis

NCT07565701 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

NETWORK

Sponsor class

Conditions

Anemia Associated With Chronic Kidney Disease

Interventions

DRUG: Epoetin alga (Epogen)/vadadustat

Sponsor

Geoff Block

Collaborators

[object Object]